Goodrx Holdings Inc (GDRX)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $1.21B
Last updated: Nov 17, 2026 at 11:05 AM ET
Goodrx Holdings Inc (GDRX) Earnings: Report Dates and Results
Goodrx Holdings (GDRX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Goodrx Holdings reported EPS of $0.04, in line with the $0.04 estimate. It beat the EPS estimate in 0 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GDRX has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.1% below the $0.09 reported for the quarter ended Dec 31, 2025.
GDRX Earnings Call
The latest GDRX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 25 quarters below that had an estimate, GDRX beat 9, missed 8 and matched 8. The widest gap in the table came in the quarter ended Sep 30, 2022, when EPS landed 75.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.04 | $0.04 | N/A | 0.00% | In line | -50.0% | 11 | 3 up, 4 down | Nov 9, 2026 | N/A |
| Jun 30, 2026 | $0.04 | $0.04 | N/A | 0.00% | In line | -55.6% | 12 | 1 up, 2 down | Aug 5, 2026 | $200.41M |
| Mar 31, 2026 | $0.07 | $0.07 | $0.05 - $0.09 | 0.00% | In line | -22.2% | 12 | 0 up, 6 down | May 6, 2026 | $194.01M |
| Dec 31, 2025 | $0.09 | $0.09 | $0.08 - $0.11 | -1.85% | Miss | 0.0% | 12 | 0 up, 6 down | Feb 25, 2026 | $194.78M |
| Sep 30, 2025 | $0.08 | $0.09 | $0.08 - $0.11 | -11.11% | Miss | 0.0% | 12 | 1 up, 6 down | Nov 4, 2025 | $196.03M |
| Jun 30, 2025 | $0.09 | $0.10 | $0.09 - $0.12 | -10.00% | Miss | +12.5% | 12 | 2 up, 3 down | Aug 6, 2025 | $203.07M |
| Mar 31, 2025 | $0.09 | $0.10 | $0.08 - $0.11 | -5.96% | Miss | +12.5% | 12 | 2 up, 3 down | May 7, 2025 | $202.97M |
| Dec 31, 2024 | $0.09 | $0.10 | $0.08 - $0.15 | -10.00% | Miss | +12.5% | 12 | 3 up, 4 down | Feb 27, 2025 | $198.58M |
| Sep 30, 2024 | $0.08 | $0.09 | $0.07 - $0.11 | -11.11% | Miss | +33.3% | 13 | 0 up, 0 down | Nov 7, 2024 | $195.25M |
| Jun 30, 2024 | $0.08 | $0.09 | $0.08 - $0.11 | -11.11% | Miss | +14.3% | 14 | 0 up, 1 down | Aug 8, 2024 | $200.61M |
| Mar 31, 2024 | $0.08 | $0.08 | $0.03 - $0.10 | 0.00% | In line | +14.3% | 15 | 0 up, 0 down | May 9, 2024 | $197.88M |
| Dec 31, 2023 | $0.08 | $0.07 | $0.01 - $0.10 | +14.29% | Beat | +14.3% | 16 | 1 up, 0 down | Feb 29, 2024 | $196.64M |
| Sep 30, 2023 | $0.06 | $0.06 | $0.04 - $0.08 | 0.00% | In line | -14.3% | 14 | 0 up, 0 down | Nov 9, 2023 | $179.96M |
| Jun 30, 2023 | $0.07 | $0.06 | $0.05 - $0.07 | +16.67% | Beat | +16.7% | 15 | 0 up, 0 down | Aug 9, 2023 | $189.68M |
| Mar 31, 2023 | $0.07 | $0.06 | $0.05 - $0.07 | +16.67% | Beat | -30.0% | 16 | 1 up, 0 down | May 10, 2023 | $183.99M |
| Dec 31, 2022 | $0.07 | $0.05 | $0.03 - $0.05 | +40.00% | Beat | -22.2% | 17 | 0 up, 0 down | Feb 28, 2023 | $184.11M |
| Sep 30, 2022 | $0.07 | $0.04 | $0.01 - $0.05 | +75.00% | Beat | -22.2% | 16 | 1 up, 0 down | Nov 8, 2022 | $187.32M |
| Jun 30, 2022 | $0.06 | $0.04 | $0.01 - $0.05 | +50.00% | Beat | -25.0% | 14 | 0 up, 1 down | Aug 8, 2022 | $191.80M |
| Mar 31, 2022 | $0.10 | $0.08 | $0.07 - $0.09 | +25.00% | Beat | +42.9% | 15 | 0 up, 0 down | May 9, 2022 | $203.33M |
| Dec 31, 2021 | $0.09 | $0.10 | $0.09 - $0.11 | -10.00% | Miss | +12.5% | 13 | 0 up, 0 down | Feb 28, 2022 | $213.26M |
| Sep 30, 2021 | $0.09 | $0.09 | $0.07 - $0.10 | 0.00% | In line | 0.0% | 13 | N/A | Nov 10, 2021 | $195.10M |
| Jun 30, 2021 | $0.08 | $0.08 | $0.07 - $0.08 | 0.00% | In line | -99.8% | 13 | N/A | Aug 12, 2021 | $176.63M |
| Mar 31, 2021 | $0.07 | $0.07 | $0.07 - $0.10 | 0.00% | In line | N/A | 13 | N/A | May 13, 2021 | $160.43M |
| Dec 31, 2020 | $0.08 | $0.06 | $0.06 - $0.07 | +33.33% | Beat | N/A | 14 | N/A | Mar 11, 2021 | $153.54M |
| Sep 30, 2020 | $0.09 | $0.08 | $0.07 - $0.11 | +12.50% | Beat | N/A | 14 | N/A | Nov 12, 2020 | $140.45M |
| Jun 30, 2020 | $42.71 | $0.10 | N/A | N/A | N/A | N/A | N/A | N/A | Jul 2, 2020 | $123.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.35, within 4 cents of the year before. It was $42.88 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.35 | N/A |
| Dec 31, 2024 | $0.33 | +17.9% |
| Dec 31, 2023 | $0.28 | N/A |
| Dec 31, 2022 | $0.30 | N/A |
| Dec 31, 2021 | $0.33 | -99.2% |
| Dec 31, 2020 | $42.88 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 7,300 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 7,277 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,736 | 14 | |
| 2025Q4 | Dec 31, 2025 | 8,776 | 16 | |
| 2025Q3 | Sep 30, 2025 | 8,314 | 14 | |
| 2025Q2 | Jun 30, 2025 | 5,394 | 9 | |
| 2025Q1 | Mar 31, 2025 | 9,575 | 14 | |
| 2024Q4 | Dec 31, 2024 | 8,141 | 16 | |
| 2024Q3 | Sep 30, 2024 | 8,326 | 17 |
2026Q2 Earnings Call
Opening remarks
Aubrey Reynolds Director of Investor Relations Thank you, operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the second quarter 2026. Joining me today are Wendy Barnes, our Chief Executive Officer; and Justin Fengler, our newly appointed Chief Financial Officer. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding management's plans, strategies, goals and objectives, our market opportunity, our anticipated financial performance, underlying trends in our business and industry, including ongoing changes in the pharmacy ecosystem, our value proposition, our long-term growth prospects, our direct and hybrid contracting approach, collaborations and partnerships with third parties, including our point-of-sale cash programs and our integrated savings program, our e-commerce strategy and our capital allocation priorities. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors. These factors, including the factors discussed in the Risk Factors section of our annual report on the Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission could cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements made on this call. Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements even if subsequent events cause our views to change. In addition, we will be referencing certain non-GAAP metrics in today's remarks. We have reconciled each non-GAAP metric to the nearest GAAP metric in the company's earnings press release, which can be found on the overview page of our Investor Relations website at investors.goodrx.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well. With that, I'll turn it over to Wendy.
Wendy Barnes Chief Executive Officer Thank you, Aubrey, and thank you to everyone for joining us today. The second quarter was a strong quarter for GoodRx. We exceeded our revenue expectations, maintained disciplined profitability and saw meaningful consumer engagement across the platform. That performance was driven by the two strategic priorities we outlined at the beginning of the year. First, Pharma Direct, which is scaling quickly due to growing manufacturer adoption of consumer direct pricing programs and sustained strength in GLP-1 access. Second, subscriptions, which are becoming a central part of how we serve and retain consumers as illustrated by the launch of our newest offering, GoodRx Companion in May.
Frequently Asked Questions About GDRX
When is Goodrx Holdings's next earnings date?
Goodrx Holdings's next earnings report is expected for Feb 23, 2027.
Did GDRX beat earnings estimates last quarter?
Goodrx Holdings reported EPS of $0.04 for the quarter ended Sep 30, 2026, in line with the $0.04 estimate.
What EPS do analysts expect from GDRX next quarter?
The consensus EPS estimate for Goodrx Holdings for the quarter ending Dec 31, 2026 is $0.08 from 15 analysts, with estimates from $0.07 to $0.11.
How often does GDRX beat earnings estimates?
Goodrx Holdings beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -4.87%.
GDRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors